{"id":"prmt5-mtap","name":"PRMT5 (MTAP-deleted cancers)","symbol":"PRMT5","route":"/targets/prmt5-mtap/","asOf":"2026-09-08","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10894","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100462","uniprot":"https://www.uniprot.org/uniprotkb/O14744/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/O14744","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1795116","open-targets":"https://platform.opentargets.org/target/ENSG00000100462","civic":"https://civicdb.org/genes/10419/summary","oncokb":"https://www.oncokb.org/gene/PRMT5","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRMT5","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PRMT5","depmap":"https://depmap.org/portal/gene/PRMT5?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000100462-PRMT5","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/10419","omim":"https://www.omim.org/entry/604045"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7413","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000099810","uniprot":"https://www.uniprot.org/uniprotkb/Q13126/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q13126","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4941","open-targets":"https://platform.opentargets.org/target/ENSG00000099810","civic":"https://civicdb.org/genes/4507/summary","oncokb":"https://www.oncokb.org/gene/MTAP","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MTAP","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=MTAP","depmap":"https://depmap.org/portal/gene/MTAP?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000099810-MTAP","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/4507","omim":"https://www.omim.org/entry/156540"}],"products":[{"id":"anvumetostat","name":"Anvumetostat","status":"phase-2","modality":"small molecule","route":"/drugs/anvumetostat/"},{"id":"azd3470","name":"AZD3470","status":"phase-2","modality":"small molecule","route":"/drugs/azd3470/"},{"id":"navlimetostat","name":"Navlimetostat","status":"phase-3","modality":"small molecule","route":"/drugs/navlimetostat/"},{"id":"tng456","name":"TNG456","status":"phase-2","modality":"small molecule","route":"/drugs/tng456/"},{"id":"tng462","name":"TNG462","status":"phase-2","modality":"small molecule","route":"/drugs/tng462/"}],"trials":[{"id":"mountaintap-30","name":"A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)","nct":"NCT07076121","phase":"2/3","status":"active"},{"id":"nct07063745","name":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","nct":"NCT07063745","phase":"2/3","status":"recruiting"},{"id":"nct06593522","name":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)","nct":"NCT06593522","phase":"2","status":"active"},{"id":"nct07283705","name":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer","nct":"NCT07283705","phase":"2","status":"recruiting"},{"id":"nct05094336","name":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","nct":"NCT05094336","phase":"1/2","status":"active"},{"id":"nct06130553","name":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","nct":"NCT06130553","phase":"1/2","status":"recruiting"},{"id":"nct06137144","name":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","nct":"NCT06137144","phase":"1/2","status":"recruiting"},{"id":"nct06188702","name":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","nct":"NCT06188702","phase":"1/2","status":"active"},{"id":"nct06810544","name":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","nct":"NCT06810544","phase":"1/2","status":"recruiting"},{"id":"nct05732831","name":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","nct":"NCT05732831","phase":"1/2","status":"recruiting"},{"id":"nct06922591","name":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","nct":"NCT06922591","phase":"1/2","status":"recruiting"}],"pathways":["synthetic-lethality-map"],"companies":["amgen","astrazeneca","bms","servier","tango-therapeutics"],"keyPapers":["paper-engstrom-cancer-discov","paper-depmap-tsherniak-cell-2017"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}